Related Experiment Video
Updated: Jul 4, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
Pegfilgrastim; a neutrophil mediated granulocyte colony stimulating factor-expanding uses in cancer chemotherapy
Mariko Morishita1, Robert C Leonard
1Imperial College Healthcare NHS trust, London W6 8RF, UK.
Background:
Currently G-CSFs such as filgrastim (Neupogen, Amgen, Inc.) and pegfilgrastim (Neulasta, Amgen, Inc.) are widely used to reduce chemotherapy-induced neutropenia. Pegfilgrastim is a novel recombinant human G-CSF and its unique neutrophil-mediated clearance allows it to be administered once per chemotherapy cycle.
Objective:
To address the pharmacology of pegfilgrastim and provide an overview of its current clinical use in cancer chemotherapy.
Methods:
Review and summary of publications on pegfilgrastim indexed in the PubMed electronic database.
Results/Conclusion:
The efficacy of pegfilgrastim is similar to or greater than that of filgrastim and an important advantage of pegfilgrastim is its schedule of administration that may be associated with greater treatment compliance and improved patient quality of life. Ongoing clinical trials continue to explore further potential uses for pegfilgrastim.
Related Concept Videos
Differentiation of Common Myeloid Progenitor Cells
Regulation of Hematopoietic Stem Cells
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
